You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
|
|---|---|
| Published in |
Journal of Clinical Oncology, June 2013
|
| DOI | 10.1200/jco.2013.49.6638 |
| Pubmed ID | |
| Authors |
Nadine J. McCleary, Jeffrey A. Meyerhardt, Erin Green, Greg Yothers, Aimery de Gramont, Eric Van Cutsem, Michael O'Connell, Christopher J. Twelves, Leonard B. Saltz, Daniel G. Haller, Daniel J. Sargent |
| Abstract |
Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| India | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 131 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 19 | 14% |
| Researcher | 19 | 14% |
| Student > Master | 15 | 11% |
| Student > Postgraduate | 12 | 9% |
| Student > Doctoral Student | 10 | 7% |
| Other | 30 | 22% |
| Unknown | 29 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 79 | 59% |
| Agricultural and Biological Sciences | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Nursing and Health Professions | 2 | 1% |
| Other | 5 | 4% |
| Unknown | 38 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2020.
All research outputs
#1,735,419
of 25,374,647 outputs
Outputs from Journal of Clinical Oncology
#4,228
of 22,046 outputs
Outputs of similar age
#14,392
of 207,874 outputs
Outputs of similar age from Journal of Clinical Oncology
#48
of 271 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,046 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,874 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 271 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.